Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy

Eur J Cancer. 2019 Jul:115:13-16. doi: 10.1016/j.ejca.2019.04.005. Epub 2019 May 10.

Authors

Takuya Maeda¹, Koji Yoshino², Kojiro Nagai², Satoe Oaku², Megumi Kato², Azusa Hiura², Hiroo Hata³

Affiliations

¹ Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. Electronic address: mtakun.bsb.hkt@gmail.com.
² Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
³ Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

PMID: 31082687
DOI: 10.1016/j.ejca.2019.04.005

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological / adverse effects*
Disease Progression
Endocrine System Diseases / chemically induced*
Endocrine System Diseases / immunology
Endocrine System Diseases / mortality
Female
Humans
Male
Melanoma / drug therapy*
Melanoma / immunology
Melanoma / mortality
Melanoma / pathology
Middle Aged
Neoplasm Staging
Nivolumab / adverse effects*
Progression-Free Survival
Retrospective Studies
Risk Assessment
Risk Factors
Skin Neoplasms / drug therapy*
Skin Neoplasms / immunology
Skin Neoplasms / mortality
Skin Neoplasms / pathology
Time Factors

Substances

Antineoplastic Agents, Immunological
Nivolumab